xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06018493</url>
    </required_header>
    <id_info>
      <org_study_id>PARADISE-HTN-II</org_study_id>
      <nct_id>NCT06018493</nct_id>
    </id_info>
    <brief_title>Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)</brief_title>
    <official_title>Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: a Drug Naive Randomized Controlled Trial (PARADISE-HTN-II)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>The Affiliated Jiangning Hospital of Nanjing Medical University</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Suzhou Municipal Hospital</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>The First Affiliated Hospital with Nanjing Medical University</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a&#xD;
        novel focused power ultrasound mediated inferior perirenal adipose tissue modification&#xD;
        therapy for essential hypertension.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The increase of visceral fat is closely related to the occurrence of hypertension, and it is&#xD;
        one of the main independent risk factors of hypertension. Visceral fat has been recognized as&#xD;
        an important endocrine organ, and a variety of factors secreted by visceral fat lead to an&#xD;
        increased risk of cardiovascular disease. Peri-renal fat is a special type of visceral fat&#xD;
        which is different from other type of visceral fat in histology, physiology, and functions.&#xD;
        The positon of peri-renal fat is more stable than other visceral fat, which might be&#xD;
        influenced by breath or body position changes.Studies have found that perirenal fat is an&#xD;
        early predictor of ASCVD, and its accumulation is closely related to the occurrence and&#xD;
        development of ASCVD. Therefore, the reduction or modification of visceral fat,especially&#xD;
        peri-renal fat , has a sufficient scientific basis for the treatment of hypertension.&#xD;
  &#xD;
        In our previous experiments, this novel focused power ultrasound can rapidly and efficiently&#xD;
        promote the perirenal adipose tissue fibrosis and control the blood pressure in the model of&#xD;
        swine. Moreover, the investigators performed a single arm, small sample study to investigate&#xD;
        the feasibility of the novel focused power ultrasound to modify the inferior perirenal&#xD;
        adipose tissue in human volunteers, showing that this kind of method was feasible and safe.&#xD;
  &#xD;
        In this study, the investigators aim to further evaluate the efficacy and safety of a novel&#xD;
        focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for&#xD;
        essential hypertension.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">September 2024</completion_date>
    <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>This is a randomized, blinded, and sham-control study. The ratio of the intervention group versus sham-control group is 1:1</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Triple (Participant, Care Provider, Investigator)</masking>
      <masking_description>The masking range includes participants, most researchers (including the study leader; subjects screening researchers; follow-up researchers; sonographers; MR scanners, members of the clinical endpoint identification committee,and etc.) except for the study statistical analysts and the therapy operators</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Ambulatory Blood Pressure</measure>
      <time_frame>From baseline to 1 month post-procedure</time_frame>
      <description>Changes of mean systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 1-month compared with baseline</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Ambulatory Blood Pressure</measure>
      <time_frame>From baseline to 3 month post-procedure</time_frame>
      <description>Changes of mean systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 3-month compared with baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Office Systolic Blood Pressure</measure>
      <time_frame>From baseline to 1 month post-procedure</time_frame>
      <description>Changes of office systolic blood pressure at 1-month compared with baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Office Systolic Blood Pressure</measure>
      <time_frame>From baseline to 3 month post-procedure</time_frame>
      <description>Changes of office systolic blood pressure at 3-month compared with baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Ambulatory Blood Pressure</measure>
      <time_frame>From baseline to 1 month post-procedure</time_frame>
      <description>Changes of mean diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 1-month compared with baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Ambulatory Blood Pressure</measure>
      <time_frame>From baseline to 3 month post-procedure</time_frame>
      <description>Changes of mean diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 3-month compared with baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Home Blood Pressure</measure>
      <time_frame>From baseline to 1 months post-procedure</time_frame>
      <description>Changes of home blood pressure at 1-month compared with baseline</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Home Blood Pressure</measure>
      <time_frame>From baseline to 3 months post-procedure</time_frame>
      <description>Changes of home blood pressure at 3-month compared with baseline</description>
    </secondary_outcome>
    <other_outcome>
      <measure>Safety evaluation</measure>
      <time_frame>From baseline to 3 month post-procedure</time_frame>
      <description>Any severe adverse events (SAE) related to intervention. The SAE were defined as acute renal failure, acute intestinal perforation, and thromboembolic events, et al.</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">80</enrollment>
    <condition>Hypertension</condition>
    <condition>Blood Pressure</condition>
    <condition>Cardiovascular Diseases</condition>
    <arm_group>
      <arm_group_label>intervention group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating) Intervention: Device: focused power ultrasound mediate inferior perirenal adipose tissue modification</description>
    </arm_group>
    <arm_group>
      <arm_group_label>sham-control group</arm_group_label>
      <arm_group_type>Sham Comparator</arm_group_type>
      <description>In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.&#xD;
  Intervention: Device: sham-control group</description>
    </arm_group>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>focused power ultrasound mediate inferior perirenal adipose tissue modification</intervention_name>
      <description>This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small &quot;cigar&quot;-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.</description>
      <arm_group_label>intervention group</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>sham-control group</intervention_name>
      <description>participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.</description>
      <arm_group_label>sham-control group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and &lt;160 mmHg, and&#xD;
               diastolic blood pressure&lt;100mmHg when not taking antihypertensive drugs for at least 1&#xD;
               month;&#xD;
  &#xD;
            2. Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥130&#xD;
               mmHg；&#xD;
  &#xD;
            3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad&#xD;
               measured by ultrasound should be at least 20mm；&#xD;
  &#xD;
            4. Individual is willing to sign the informed consent of the study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Individual with office systolic blood pressure (SBP) ≥ 160 mmHg and/or office&#xD;
               diastolic blood pressure(DBP)≥ 100mmHg;&#xD;
  &#xD;
            2. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension,&#xD;
               renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome,&#xD;
               aortic coarctation, obstructive sleep apnea hypopnea syndrome)；&#xD;
  &#xD;
            3. Individuals with ≥ 3 cardiovascular risk factors (male&gt;55 years old, female&gt;65 years&#xD;
               old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or&#xD;
               impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl),&#xD;
               HDL-C&lt;1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset&#xD;
               of cardiovascular disease, age of onset of first degree relatives&lt;50 years old;&#xD;
               Abdominal obesity, waist circumference: male&gt;90cm, female&gt;85cm or BMI&gt;28kg/m2) or&#xD;
               hypertensive target organ damage;&#xD;
  &#xD;
            4. Individuals taking other medications that may affect blood pressure (such as&#xD;
               glucocorticoids);&#xD;
  &#xD;
            5. Individual with history of kidney or kidney surrounding tissue surgery;&#xD;
  &#xD;
            6. Individuals with impairment of liver or kidney function (ALT, AST or creatinine&#xD;
               greater than 2 times of the upper limit of normal reference);&#xD;
  &#xD;
            7. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular&#xD;
               accident or transient ischemic attack within 6 months of enrollment;&#xD;
  &#xD;
            8. Individual with type 1 diabetes or uncontrolled type 2 diabetes；&#xD;
  &#xD;
            9. Individual with uncontrolled thyroid dysfunction;&#xD;
  &#xD;
           10. Individual with urinary calculi or hematuria；&#xD;
  &#xD;
           11. Individual with atrial fibrillation;&#xD;
  &#xD;
           12. Individual with severe structural heart disease (e.g. valvular heart disease,&#xD;
               cardiomyopathy, congenital heart disease);&#xD;
  &#xD;
           13. Individual with second degree and above atrioventricular block and/or sick sinus&#xD;
               syndrome;&#xD;
  &#xD;
           14. Individual with abnormal coagulation function;&#xD;
  &#xD;
           15. Individual with infected waist skin;&#xD;
  &#xD;
           16. Individual with malignant tumor;&#xD;
  &#xD;
           17. Individual is pregnant, nursing or planning to be pregnant;&#xD;
  &#xD;
           18. Individual is unwilling to sign informed consent;&#xD;
  &#xD;
           19. Individual fails to complete the screening period.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>65 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Xiangqing Kong</last_name>
      <phone>13951610265</phone>
      <email>kongxq@njmu.edu.cn</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Wei Sun</last_name>
      <phone>13815860536</phone>
      <email>shunwee@126.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Jiangsu Province Hospital/The Affiliated Hospital of Nanjing Medical University</name>
        <address>
          <city>Nanjing</city>
          <state>Jiangsu</state>
          <zip>210000</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Xiangqing Kong, MD</last_name>
        <phone>13951610265</phone>
        <email>kongxq@njmu.edu.cn</email>
      </contact>
      <contact_backup>
        <last_name>Wei Sun, MD</last_name>
        <phone>13815860536</phone>
        <email>shunwee@126.com</email>
      </contact_backup>
    </location>
    <location>
      <facility>
        <name>The Affiliated Jiangning Hospital of Nanjing Medical University</name>
        <address>
          <city>Nanjing</city>
          <state>Jiangsu</state>
          <zip>210000</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Yuqing Zhang, MD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Suzhou Municipal Hospital</name>
        <address>
          <city>Suzhou</city>
          <state>Jiangsu</state>
          <zip>215000</zip>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Yanhui Sheng, MD</last_name>
      </contact>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <reference>
      <citation>Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004 Jun 15;140(12):992-1000. doi: 10.7326/0003-4819-140-12-200406150-00008.</citation>
      <PMID>15197016</PMID>
    </reference>
    <reference>
      <citation>Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, Khera A, McGuire DK, de Lemos JA, Turer AT. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014 Sep 9;64(10):997-1002. doi: 10.1016/j.jacc.2014.05.057.</citation>
      <PMID>25190234</PMID>
    </reference>
    <reference>
      <citation>Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005 Dec;330(6):280-9. doi: 10.1097/00000441-200512000-00005.</citation>
      <PMID>16355012</PMID>
    </reference>
    <reference>
      <citation>Li P, Liu B, Wu X, Lu Y, Qiu M, Shen Y, Tian Y, Liu C, Chen X, Yang C, Deng M, Wang Y, Gu J, Su Z, Chen X, Zhao K, Sheng Y, Zhang S, Sun W, Kong X. Perirenal adipose afferent nerves sustain pathological high blood pressure in rats. Nat Commun. 2022 Jun 6;13(1):3130. doi: 10.1038/s41467-022-30868-6.</citation>
      <PMID>35668093</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 25, 2023</study_first_submitted>
    <study_first_submitted_qc>August 25, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 30, 2023</study_first_posted>
    <last_update_submitted>August 29, 2023</last_update_submitted>
    <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
      <investigator_full_name>Xiangqing Kong</investigator_full_name>
      <investigator_title>Head of Cardiology</investigator_title>
    </responsible_party>
    <keyword>Hypertension</keyword>
    <keyword>Cardiovascular disease</keyword>
    <keyword>Focused ultrasound</keyword>
    <keyword>Novel method</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Hypertension</mesh_term>
      <mesh_term>Cardiovascular Diseases</mesh_term>
      <mesh_term>Essential Hypertension</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06018493
  org study id: PARADISE-HTN-II
  nct id: NCT06018493
  lead sponsor: 
  collaborator: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a
        novel focused power ultrasound mediated inferior perirenal adipose tissue modification
        therapy for essential hypertension.
  The increase of visceral fat is closely related to the occurrence of hypertension, and it is
        one of the main independent risk factors of hypertension. Visceral fat has been recognized as
        an important endocrine organ, and a variety of factors secreted by visceral fat lead to an
        increased risk of cardiovascular disease. Peri-renal fat is a special type of visceral fat
        which is different from other type of visceral fat in histology, physiology, and functions.
        The positon of peri-renal fat is more stable than other visceral fat, which might be
        influenced by breath or body position changes.Studies have found that perirenal fat is an
        early predictor of ASCVD, and its accumulation is closely related to the occurrence and
        development of ASCVD. Therefore, the reduction or modification of visceral fat,especially
        peri-renal fat , has a sufficient scientific basis for the treatment of hypertension.
  
        In our previous experiments, this novel focused power ultrasound can rapidly and efficiently
        promote the perirenal adipose tissue fibrosis and control the blood pressure in the model of
        swine. Moreover, the investigators performed a single arm, small sample study to investigate
        the feasibility of the novel focused power ultrasound to modify the inferior perirenal
        adipose tissue in human volunteers, showing that this kind of method was feasible and safe.
  
        In this study, the investigators aim to further evaluate the efficacy and safety of a novel
        focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for
        essential hypertension.
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: This is a randomized, blinded, and sham-control study. The ratio of the intervention group versus sham-control group is 1:1
  primary purpose: Treatment
  masking: Triple (Participant, Care Provider, Investigator)
  masking description: The masking range includes participants, most researchers (including the study leader; subjects screening researchers; follow-up researchers; sonographers; MR scanners, members of the clinical endpoint identification committee,and etc.) except for the study statistical analysts and the therapy operators
  measure: Ambulatory Blood Pressure
  time frame: From baseline to 1 month post-procedure
  description: Changes of mean systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 1-month compared with baseline
  measure: Ambulatory Blood Pressure
  time frame: From baseline to 3 month post-procedure
  description: Changes of mean systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 3-month compared with baseline
  measure: Office Systolic Blood Pressure
  time frame: From baseline to 1 month post-procedure
  description: Changes of office systolic blood pressure at 1-month compared with baseline
  measure: Office Systolic Blood Pressure
  time frame: From baseline to 3 month post-procedure
  description: Changes of office systolic blood pressure at 3-month compared with baseline
  measure: Ambulatory Blood Pressure
  time frame: From baseline to 1 month post-procedure
  description: Changes of mean diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 1-month compared with baseline
  measure: Ambulatory Blood Pressure
  time frame: From baseline to 3 month post-procedure
  description: Changes of mean diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring at 3-month compared with baseline
  measure: Home Blood Pressure
  time frame: From baseline to 1 months post-procedure
  description: Changes of home blood pressure at 1-month compared with baseline
  measure: Home Blood Pressure
  time frame: From baseline to 3 months post-procedure
  description: Changes of home blood pressure at 3-month compared with baseline
  measure: Safety evaluation
  time frame: From baseline to 3 month post-procedure
  description: Any severe adverse events (SAE) related to intervention. The SAE were defined as acute renal failure, acute intestinal perforation, and thromboembolic events, et al.
  arm group label: intervention group
  arm group type: Experimental
  description: In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating) Intervention: Device: focused power ultrasound mediate inferior perirenal adipose tissue modification
  arm group label: sham-control group
  arm group type: Sham Comparator
  description: In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
  Intervention: Device: sham-control group
  intervention type: Device
  intervention name: focused power ultrasound mediate inferior perirenal adipose tissue modification
  description: This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small "cigar"-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.
  arm group label: intervention group
  intervention type: Device
  intervention name: sham-control group
  description: participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
  arm group label: sham-control group
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 65 Years
  healthy volunteers: No
  last name: Xiangqing Kong
  phone: 13951610265
  email: kongxq@njmu.edu.cn
  last name: Wei Sun
  phone: 13815860536
  email: shunwee@126.com
  facility: 
  contact: 
  contact backup: 
  facility: 
  contact: 
  facility: 
  contact: 
  country: China
  citation: Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004 Jun 15;140(12):992-1000. doi: 10.7326/0003-4819-140-12-200406150-00008.
  PMID: 15197016
  citation: Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, Khera A, McGuire DK, de Lemos JA, Turer AT. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014 Sep 9;64(10):997-1002. doi: 10.1016/j.jacc.2014.05.057.
  PMID: 25190234
  citation: Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005 Dec;330(6):280-9. doi: 10.1097/00000441-200512000-00005.
  PMID: 16355012
  citation: Li P, Liu B, Wu X, Lu Y, Qiu M, Shen Y, Tian Y, Liu C, Chen X, Yang C, Deng M, Wang Y, Gu J, Su Z, Chen X, Zhao K, Sheng Y, Zhang S, Sun W, Kong X. Perirenal adipose afferent nerves sustain pathological high blood pressure in rats. Nat Commun. 2022 Jun 6;13(1):3130. doi: 10.1038/s41467-022-30868-6.
  PMID: 35668093
  responsible party type: Principal Investigator
  investigator affiliation: The First Affiliated Hospital with Nanjing Medical University
  investigator full name: Xiangqing Kong
  investigator title: Head of Cardiology
  mesh term: Hypertension
  mesh term: Cardiovascular Diseases
  mesh term: Essential Hypertension
  sharing ipd: No